[Treatment of older patients with multiple myeloma can be successful with the use of pegylated liposomal doxorubicin, melphalan and prednisone.]

In the context of medical practice, melphalan in combination with prednisolone has traditionally been used as the main treatment for patients with multiple myeloma (MM) when high-dose therapy is not an appropriate option. This scientific paper presents an analysis of the results of a study aimed at studying the potential safety and effectiveness of adding a regimen with the inclusion of pegylated liposomal doxorubicin (PLD) to the standard course of treatment with melphalan and prednisolone in the first six cycles of initial therapy in patients with MM over the age of 65 who had not previously been treated. As part of the study, a group of 45 patients with an average age of 79 years (73-86 years) was formed, where the ratio of men and women was 18:17. Thus, the results of this study confirm the effectiveness of using vel-PLD in these dosages for the treatment of diseases, while emphasizing the percentage of complete disappearance of symptoms, improvement in the quality of treatment.